Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=138 Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Urge Urinary Incontinence
Primary: Baseline Sexual Satisfaction Between Matched Female and Male Partners — 4.2; 4.8 score on a scale — p=.16
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
N/A N=61 Mindfulness + tDCS to Reduce Urgency Incontinence in Women
Urinary Incontinence, Urge
Primary: Feasibility of Study Procedures Measured by Percentage of Participants Starting Intervention Who Complete the Study — 100; 90.4; 100 percentage of participants who…
N/A N=400 Improving Care for Women With Urinary Incontinence (EMPOWER)
Urinary Incontinence
Primary: Change in Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) — 8.4; 9.0; 9.9; 8.9…
N/A N=70 The Urinary Incontinence Treatment Study
Urinary Incontinence · Sarcopenia
Primary: Number of Urinary Incontinence Episodes — 4.3; 2.7 number of incontinence episodes
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
N/A N=240 A Group-Based Therapeutic Yoga Intervention for Urinary Incontinence in Ambulatory Older Women
Stress Incontinence, Female · Stress Incontinence, Urinary · Stress Incontinence
Primary: Change From Baseline in Total Urinary Incontinence Episodes — -1.99; -1.7 episodes per day — p=0.056
N/A N=250 Web-based Management of Female Stress Urinary Incontinence
Female Stress Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 10.3; 10.4; 7.3; 6.9 units on a scale — p=0.27
N/A N=279 Improving Urinary Continence and Quality of Life in Prostate Cancer Patients
Urinary Incontinence
Primary: Amount of Urinary Leakage — 23.2; 22.3; 31.5; 11 grams
Phase 4 N=645 Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Frequency of Urge Urinary Incontinence Episodes at Week 12. — -2.5; -1.8 episodes — p=<0.001
N/A N=50 Continence Pessary Versus Disposable Intravaginal Device Trial
Female Stress Incontinence
Primary: Treatment Success — 8; 9 Participants
N/A N=36 A Randomized Controlled Trial of the Uresta Continence Pessary
Stress Urinary Incontinence
Primary: A 50% Reduction in Pad Test Weight — 12; 4 Participants
N/A N=47 Dose-response of Physical Exercise on Pelvic Floor Muscle Function in Postmenopausal Women With Urinary Incontinence
Urinary Incontinence · Pelvic Floor Muscle Weakness
Primary: Pelvic Floor Muscle Function Measured by Digital Palpation — 4.00; 3.25; 3.75 score on a scale
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI
N/A N=7 Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: Mean Percentage of Pad Weight Gain (PWG) Change — 90.8; 98.5; 99.3; 89.3 Mean percentage of PWG change
N/A N=123 Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women
Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 7.0; 9.8 score on a scale — p=0.001
Phase 4 N=168 Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Urgency Urinary Incontinence
Primary: Responder (Yes/no) — 23; 39; 36; 17 Participants
Phase 2 N=22 Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients
Stress Urinary Incontinence
Primary: Change From Baseline in Opening Urethral Pressure (OUP) at Day 7 — 49.86; 49.86; 49.86; 47.92 centimeter of water (cmH2O) — p=0.4907
Phase 2 N=94 Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
Urinary Incontinence
Primary: Percentage of Participants With a Decrease in Leakage Events of 30% or More. — 60.6; 61.7 Percentage of participants — p=.92
Phase 2 N=127 Acupuncture for Urinary Incontinence
Urinary Incontinence
Primary: Percent Change in Incontinent Episodes — -38.26; -15.29 percent change in incontinent episodes — p=0.02
N/A N=163 Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder
Overactive Bladder
Primary: Evaluate Proportion of Responders Based on the Change From Baseline in Mean Urgency (Urinary) Incontinence Episodes (Leaks) Between the Active and Sham Treatment Groups…
N/A N=90 A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence (SUI)
Stress Urinary Incontinence (SUI)
Primary: Percentage of Responders for Pad Weight Gain or SUI Episodes — 69 percentage of subjects
N/A N=56 Lessening Incontinence Through Low-impact Activity
Urinary Incontinence
Primary: Total Incontinence Frequency — -2.8; -1.9 episodes per day — p=0.13
N/A N=64 Enhancing Conservative Treatment for Urge Incontinence
Urinary Incontinence
Primary: Change in Incontinent Episodes Immediately Post-treatment — -88.5; -78.3 percentage change — p=.16
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=221 Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence
Urinary Incontinence
Primary: Change of Stamey Grade From Baseline to 12 Months. — -1.17 units on a scale — p=<0.001
N/A N=23 Use of the Leva Incontinence System in Treating Bladder Incontinence.
Stress Urinary Incontinence
Primary: Symptoms of Urinary Incontinence at Baseline and at 6 Weeks — 27.5; 1.1 score on a scale — p=0.0001
Phase 3 N=87 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary Incontinence
Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day
N/A N=152 Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
Urinary Incontinence, Urge
Primary: Percent Change in Urgency Urinary Incontinence Episodes — 73; 88.6 percentage change in median UUI episodes — p=<.025